Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
=== FRIDOC database === FRIDOC is the most comprehensive database in the world dedicated to refrigeration. It contains over 110,000 references to documents in all domains of refrigeration. A large number of the documents referenced in FRIDOC are scientific and technical. FRIDOC also contains many review articles, documents on economic data and statistics, articles dealing with regulations and standardisation, etc.
== Career == King joined Massachusetts Institute of Technology in 1959 as an assistant professor of chemical engineering to become director of the School of Chemical Engineering Practice station at the Exxon (then Esso) Bayway refinery in New Jersey. In 1963, King joined University of California, Berkeley as assistant professor of chemical engineering, becoming associate professor in 1966 and full professor in 1969. From 1967 to 1972, he served as the vice chairman of Department of Chemical Engineering. He then served as the chairman of the department from 1972 to 1981. In 1981, King was appointed as the dean of College of Chemistry and later in 1987 as the provost of the Professional Schools and Colleges, a position in which he served until 1994. At the time of his appointment, King was the first chemical engineer to become dean of the College of Chemistry at Berkeley. King was appointed the vice provost for research for the entire nine-campus University of California in 1994. In 1995 he became provost and senior vice president for academic affairs, again university-wide. During his time as UC provost, King helped launch the new, tenth UC campus at Merced, the California Digital Library, and eScholarship, the University of California's open access, electronic repository for publications by UC authors. He returned to UC Berkeley in 2004 as the director of Center for Studies in Higher Education, serving in this position for a full decade until 2014.
==== Photolithography ==== Ultraviolet radiation is used for very fine resolution photolithography, a procedure wherein a chemical called a photoresist is exposed to UV radiation that has passed through a mask. The exposure causes chemical reactions to occur in the photoresist. After removal of unwanted photoresist, a pattern determined by the mask remains on the sample. Steps may then be taken to "etch" away, deposit on or otherwise modify areas of the sample where no photoresist remains. Photolithography is used in the manufacture of semiconductors, integrated circuit components, and printed circuit boards. Photolithography processes used to fabricate electronic integrated circuits presently use 193 nm UV and are experimentally using 13.5 nm UV for extreme ultraviolet lithography.
A representative of the Swedish Olympic Committee said, "I see it as ill-conceived, short-sighted and foolhardy and something other than sport." The UK Anti-Doping organisation said in a statement that "UKAD's mission is to protect sport from doping cheats. There is no place in sport for performance enhancing drugs, nor the Enhanced Games." Travis Tygart, CEO of the United States Anti-Doping Agency (USADA), said: "farcical … likely illegal in many [US] states" and "a dangerous clown show, not real sport." Rahul Gupta, director of the Office of National Drug Control Policy, stated that the Biden administration had deep concerns regarding TEG. The China Anti-Doping Agency (CHINADA) stated that it is in "firm opposition to any attempt to portray doping as so-called scientific advancements, and calls on the global sports community to stand united in rejecting the Enhanced Games." TEG filed a lawsuit in the United States District Court for the Southern District of New York in Manhattan against several sporting bodies in August 2025, including World Aquatics and WADA. The allegation is that these organizations are violating anti-trust laws by preventing athletes from competing in TEG. United States District Judge Jesse Furman dismissed the lawsuit in a 33-page order in November 2025. The organization chose not to refile the lawsuit within the 30-day deadline, and the court closed the case.
Macrolides Azithromycin Clarithromycin Erythromycin When taken independently, erythromycin has been shown to cause both QT prolongation and TdP. Erythromycin works inhibiting the CYP3A protein. Patients who have low CYP3A activity and are also concurrently taking other medications such as disopyramide, which can lead to QT prolongation and TdP. Fluoroquinolones Ciprofloxacin Levofloxacin Moxifloxacin
Sources: en.wikipedia.org
RNA sequences at lengths of 30 nucleotides, 60 nucleotides, 100 nucleotides, and 140 nucleotides, were capable of catalysis of "the synthesis of three common coenzymes, CoA, NAD, and FAD, from their precursors, 4'-phosphopantetheine, NMN, and FMN, respectively".
Initial letters are used where there is no ambiguity: C cysteine, H histidine, I isoleucine, M methionine, S serine, V valine. No other amino acids in this set begin with each of those letters. Where arbitrary assignment is needed, the structurally simpler amino acids are given precedence: A alanine, G glycine, L leucine, P proline, T threonine. For example, alanine is simpler than arginine or asparagine, the other amino acids starting with "a". F PHenylalanine and R aRginine are assigned by being phonetically suggestive, W tryptophan is assigned based on the double ring being visually suggestive to the bulky letter W, K lysine and Y tyrosine are assigned as alphabetically nearest to their initials L and T (note that U was avoided for its similarity with V, while X was reserved for undetermined or atypical amino acids); for tyrosine the mnemonic tYrosine was also proposed, D aspartate was assigned arbitrarily, with the proposed mnemonic asparDic acid; E glutamate was assigned in alphabetical sequence being larger by merely one methylene –CH2– group, N asparagine was assigned arbitrarily, with the proposed mnemonic asparagiNe; Q glutamine was assigned in alphabetical sequence of those still available (note again that O was avoided due to similarity with D), with the proposed mnemonic Qlutamine.
== History == Lean is thought to have developed in Houston around the 1960s, when blues musicians would take Robitussin and cut it with beer. Later, when wine coolers came onto the market, they substituted for beer. These blues musicians lived in Houston's Fifth Ward, Third Ward, and South Park neighborhoods and the practice was taken up by the generation of rappers growing up in the same parts of the city. In the 1980s and 1990s the formula changed to using codeine promethazine cough syrup, somewhat like the glutethimide and codeine combination that was popular from the 1970s up to the early 1990s. Codeine-based cough syrups were also turned to as an alternative to pentazocine/tripelennamine ("T's and blues") after the pharmaceutical industry added naloxone to the tablets, effectively blocking their potential for abuse. Lean remained a local phenomenon in Houston until the 1990s, when the American rapper DJ Screw released several tunes mentioning the drink in his mixtapes, which were extremely popular in the Houston area. DJ Screw's music was particularly appropriate for Houston's climate.
== Post-presidency (2022–present) == At the end of his presidency, Duterte returned to Davao City and kept a low profile. Former President Gloria Macapagal-Arroyo, a political ally of Duterte, convinced him in September 2023 to participate in the Philippine political landscape. In January 2023, Duterte resumed hosting his weekly show, Gikan sa Masa, Para sa Masa (From the Masses, For The Masses), on SMNI; co-hosted by Duterte's friend and spiritual adviser Pastor Apollo Quiboloy, Duterte would speak about current political issues besetting the country. Some of Duterte's strong statements in the show, such as his opposition to the expansion of the Enhanced Defense Cooperation Agreement (EDCA) sites in the Philippines, attracted attention and were covered by the media.
Sources: en.wikipedia.org
When clubbing is observed, pseudoclubbing should be excluded before making the diagnosis. Associated conditions may be identified by taking a detailed medical history—particular attention is paid to lung, heart, and gastrointestinal conditions—and conducting a thorough clinical examination, which may disclose associated features relevant to the underlying diagnosis. Additional studies, such as a chest X-ray and a chest CT-scan, may reveal otherwise asymptomatic cardiopulmonary disease.
In 1H Magnetic Resonance Spectroscopy each proton can be visualized at a specific chemical shift (peak position along x-axis) depending on its chemical environment. This chemical shift is dictated by neighboring protons within the molecule. Therefore, metabolites can be characterized by their unique set of 1H chemical shifts. The metabolites that MRS probes for have known (1H) chemical shifts that have previously been identified in NMR spectra. These metabolites include:
As of 2019, there were an estimated 72,000 centenarians living in the U.S.; the 2020 census officially counted 80,139, and the 2010 census had 53,364. However, the U.S. Census Bureau claimed in 1999 that as many as a third of people stating their age as over 100 might be exaggerating. In the United States, centenarians may request a letter of congratulation from the president of the United States to mark their longevity. Strom Thurmond became the first sitting Senator to reach 100 on 5 December 2002. Jimmy Carter became the first former president to reach the age of 100 on 1 October 2024. Today also presents a segment honoring centenarians and older, sponsored by Smuckers. The tradition was created in 1983 by weather presenter Willard Scott, and is now presented by his successor Al Roker. In the state of New Mexico, centenarians have been exempt from state income tax since tax year 2002, if they are not dependents of another taxpayer.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.